Want to see FR:ALMDT full AI Analyst Report?
ALMDT Stock Chart & Stats
€4.04
€0.10(2.35%)
At close: 4:00 PM EDT
€4.04
€0.10(2.35%)
Day’s Range― - ―
52-Week Range€1.85 - €7.27
Previous CloseN/A
Volume515.80K
Average Volume (3M)465.96K
Market Cap
€202.66M
Enterprise Value€180.92
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding49,048,060
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€25.43M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRecurring top-line expansion (2025: +21.5%) indicates the core offering is gaining traction with biopharma and clinical customers. Durable revenue growth supports scale benefits over 2-6 months and increases the chance to leverage fixed costs into improved future margins.
Clear Focus On Oncology Imaging AIA focused product set targeting oncology imaging and tumor quantification aligns with structural demand in cancer drug development and diagnostic automation. Specialization builds domain expertise, data assets and regulatory pathways that are durable competitive advantages over the medium term.
Multiple Revenue Streams (services + Software + Diagnostics)A mix of clinical-trial imaging services, SaaS/software licensing and potential diagnostic product sales diversifies cash sources and reduces reliance on one customer type. This multi-channel model supports more stable revenue and upsell opportunities as regulatory clearances progress.
Bears Say
Persistent Deep UnprofitabilityLarge, ongoing net losses reduce ability to self-fund growth and increase reliance on external capital. Over months this heightens dilution and constrains investment in product development or commercial scaling, undermining long-term competitiveness if losses persist.
Consistently Negative Operating Cash FlowRepeated negative operating cash flow signals structural cash burn from operations. Without material turnaround in cash conversion, the company must raise funds, which can be dilutive or costly and limit strategic flexibility for R&D, regulatory submissions, or market expansion.
Weakened Balance Sheet With Negative EquityNegative shareholders' equity reflects accumulated losses and reduces financial resilience. A weak capital base makes absorbing shocks harder, increases refinancing risk, and constrains ability to pursue partnerships or scale commercial operations over the medium term.
Median Technologies News
ALMDT FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.85 and its highest was €7.27 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €202.66M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 69 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 49,048,060 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in FR:ALMDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―